Nature is a prolific pharmacist. Aspirin, the blood thinner warfarin and metformin for diabetes all trace back to plants, discovered by serendipity before being transformed into drugs by modern chemistry.
Biotech’s latest unicorn, the closely held firm Enveda, wants to shave a few centuries off the journey from nature to the medicine cabinet, using artificial intelligence to scour thousands of plants for potential next breakthroughs.
That promise helped the Boulder, Colorado, company close a $150 million Series D, Enveda said Thursday, lifting its valuation above $1 billion and bringing its total venture funding to $517 million. Enveda, founded in ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.